PHA Copolymer Biosynthesis via Recombinant E. coli Pathway Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing medium-chain-length polyhydroxyalkanoate (MCL) biopolymers lack control over repeating unit composition, limiting the range of mechanical properties and applicability of PHA plastics, and are unsustainable due to reliance on costly agricultural sources, hindering market penetration and environmental impact.
Innovation Solution
Development of recombinant Escherichia coli strains with disrupted β-oxidation pathways and engineered nucleic acid constructs encoding enoyl-CoA hydratase, β-ketothiolase, and type II polyhydroxyalkanoate synthase genes to biosynthesize PHB-co-MCL copolymers from diverse substrates, including waste streams, allowing for controllable production of PHA homopolymers and copolymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If recombinant E. coli strains with disrupted β-oxidation pathways are used to biosynthesize PHA copolymers from diverse substrates, then the composition control and mechanical properties are improved, but the device complexity increases
Solution Approach 1:
The patent segments the PHA biosynthesis pathway into distinct functional modules: (1) substrate uptake and activation enzymes, (2) β-oxidation pathway enzymes (disrupted), (3) PHA synthase, and (4) regulatory elements. By disrupting specific genes (fadB, fadJ) and introducing others (phaC1, phaA, phaB, phaJ4), the system achieves precise compositional control through modular genetic engineering.
Solution Approach 2:
The patent changes metabolic parameters by altering the β-oxidation pathway disruption level and adjusting substrate concentration ratios. By controlling the degree of pathway disruption and substrate availability, the system tunes PHA copolymer composition (e.g., PHB-co-MCL ratios) to achieve desired mechanical properties.
2Ease of manufacture
If PHA copolymers are produced from waste streams, then production costs and environmental footprint are reduced, but manufacturing precision of repeating unit composition becomes more difficult to control
Solution Approach 1:
The patent implements feedback control through regulatory proteins (Cro, Crc) that monitor substrate availability and adjust enzyme expression accordingly. This allows the system to maintain compositional precision even when using variable waste stream substrates by dynamically regulating the metabolic pathway based on actual substrate concentration.
Solution Approach 2:
The patent compensates for waste stream variability by adjusting operational parameters such as substrate concentration ratios, incubation time, and temperature. These parameter changes allow the system to maintain consistent PHA copolymer composition despite fluctuations in waste stream composition.
3Productivity
If the β-oxidation pathway is disrupted to enhance PHA production, then productivity increases, but loss of energy increases due to metabolic redirection
Solution Approach 1:
The patent converts the harmful effect of β-oxidation (which would degrade PHA precursors) into a benefit by strategically disrupting the pathway. The disruption prevents energy-wasting β-oxidation of PHA monomers while redirecting metabolic flux toward PHA synthesis, effectively turning a potential energy loss mechanism into an energy-saving strategy that enhances productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the production of PHA copolymers with tunable composition and improved mechanical properties, reducing production costs and environmental footprint by utilizing waste materials, thereby enhancing the competitiveness and sustainability of biodegradable plastics.
Implementation Method 1
engineered nucleic acid constructs encoding enoyl-CoA hydratase, β-ketothiolase, and type II polyhydroxyalkanoate synthase genes to biosynthesize PHB-co-MCL copolymers
Implementation Method 2
recombinant Escherichia coli strains with disrupted β-oxidation pathways
Data Source
AI summary
The present disclosure provides a microorganism and expression cassette useful for biologically producing PHA ho-mopolymers and/or PHA copolymers, including PHB-co-MCL copolymers of controllable or predetermined composition. In embodiments, the present disclosure provides a nucleic acid construct suitable for use in a microorganism and/or expression cassette including a nucleic acid construct including: one or more genes comprising a phaJ4 gene, a phaA gene, a phaB gene, a phaC1 gene, or combinations thereof; a cDNA that encodes one or more proteins comprising an enoyl-CoA hydratase 2, a β-ketothiolase, an acetoacetyl-CoA reductase, a type II poly hydroxyalkanoate synthase, or combinations thereof; or one or more nucleic acid sequences that encode one or more proteins including an enoyl-CoA hydratase 2, a β-ketothiolase, an acetoacetyl-CoA reductase, a type II poly hydroxyalkanoate synthase, or combinations thereof.